Development of a predictive model to distinguish prostate cancer from benign prostatic hyperplasia by integrating serum glycoproteomics and clinical variables

Table 4 Candidates selected after TMT-B experiment with relative fold-changes (FC)

Gene	Master protein	Annotated sequence	FC	Ref	Charge	p-value
PZP	P20742	QEVCEEFSQQLNSNGCITQQVHTK	1.53		4	0.052
PZP	P20742	TFSSMTCASGANVSEQLSLK	1.41		3	0.077
ENG	P17813	QNGTWPR	1.22		2	0.014
UMOD	P07911	QDFNITDISLLEHR	1.21		3	0.085
PON1	P27169	HANWTLTPLK	1.20		2	0.096
TFRC	G3V0E5	DFEDLYTPVNGSIVIVR	1.20		2	0.095
LAMB1	P07942	LSDTTSQSNSTAK	1.15	[27]	2	0.090
NCAM1	H7BYX6	NISSEEK	1.11	[14]	2	0.082
GPLD1	P80108	NINYTER	1.11	[28]	2	0.098
PTPRJ	Q12913	SNDTAASEYK	1.09	[29]	2	0.031

Glycosylation site is in bold + underlined (N). For precursors having a FC < 1.2, the corresponding Reference used for their selection is cited in the “Ref.” column

ISSN: 1559-0275